羅海彬 博士、海南大學二級教授、365英国上市官网在线院長，目前為國家重大人才工程獲得者（2021年）、政府特殊津貼專家（2023）、  海南省B類人才（2021年）、廣東醫學-（2018年）、國家重點研發計劃首席科學家（2017年）、廣東省珠江學者（2016 年）、國家-（2015年）。2021年11月榮獲國際超算“戈登貝爾”提名獎（藥學界首次入圍該獎，戈登貝爾獎是國際上高性能 計算應用領域的最高學術獎項），2019年榮獲中國化學會青年計算化學家獎和2014年榮獲中國藥學會施維雅青年藥物化學獎。20 20年11月榮獲民革中央的“抗擊新冠肺炎疫情新冠肺炎疫情先進個人”稱号和廣東民革省委會的“抗擊新冠肺炎疫情先進個人”稱号。1999年7月本科 畢業于廈門大學，2002年7月碩士畢業于廈門大學、2005年10月博士畢業于香港浸會大學，2006年12月-2020年12月工作于中山大學藥 學院，先後擔任副教授、教授和副院長。2021年1月起任365英国上市官网在线首任院長，籌建海南大學新藥篩選與評價平台。多年來 主要從事新藥研發工作（包括藥物設計、有機合成、藥物篩選和靶标驗證等），已創制新冠肺炎治療藥物雙嘧達莫和2個臨床前 候選藥物（已實現了成果轉化）。

E-Mail：hbluo@hainanu.edu.cn, 20817504@qq.com

 1.教育背景

2.教學情況

主講計算機輔助藥物設計

3.科研情況

面向突發重大公共疫情和國家/軍隊的重大需求，聚焦于藥物設計新方法、肺部炎症性疾病、皮膚類疾病新藥研發，構建了基于自由能微擾的藥/靶結合強度預測等核心算法，實現部分方法的新突破及國産化，成功應用于新冠肺炎、缺氧性肺動脈高壓和肺纖維化等肺部炎症性疾病新藥研發。創制了新冠肺炎治療藥物雙嘧達莫、兩個靶向磷酸二酯酶PDE臨床前候選新藥1607和LW33（兩個均實現成果轉化）、十個PDEs成藥性候選分子。在Cell、Nat Sci Rev、PNAS、Acta Pharm Sin B、J Med Chem等國内外權威期刊發表150多篇論文；申請專利30多項；獲批1項國家重點研發計劃和6項國自然基金，科研經費超過3000萬。

4.研究領域

藥物設計新方法、PDE靶向藥物

5.社會兼職

中國化學會計算機化學專業委員會委員

廣東藥學會藥物化學專業委員會副主委兼秘書長

6.代表性項目

• 國家自然科學基金面上項目：新型磷酸二酯酶PDE1選擇性抑制劑的發現、成藥性優化和抗肺纖維化作用研究，2021.01-2024.12

• 國家自然科學基金面上項目：特異性識别磷酸二酯酶PDE8的黃嘌呤類衍生物：設計、抗血管性癡呆活性及作用機制研究，2019.01-2022.12

• 國家重點研發計劃：基于E 級高性能計算生物醫藥應用軟件系統研制及應用 2017.07-2020.12

• 國自然優秀青年基金，藥物設計與發現,2016.01-2018.12

• 廣東省“珠江學者”特聘教授項目，2016.10-2021.09

• 廣州市科技機會科學研究重點項目，抗肺動脈高壓首創藥物2058對磷酸二酯酶PDE5變構位點的調節機制、結構優化和成藥性研究，2019.04-2022.03，

7.代表性成果

2000年後，在Cell、Natl Sci Rev、PNAS、ACS Nano、ACS Catalysis、Acta Pharm Sin B、J Med Chem等國内外雜志發表論文150多篇（*表示為通訊作者）。

1）Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis. Zhou Q, Le M, Yang Y, Wang W, Huang Y, Wang Q, Tian Y, Jiang M, Rao Y,* Luo, H.-B*., Wu Y.* Acta Pharm. Sin. B. 2023, 13(3): 1180-1191.

2）Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia. Wu XN, Zhou Q, Huang YD, Xie X, Li Z, Wu Y*, Luo, H.-B*. Acta Pharm. Sin. B. 2022,12(7):3103-3112.

3）Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. Huang MX, Tian YJ, Han C, Liu RD, Xie X, Yuan Y, Yang YY, Li Z, Chen J*, Luo, H.-B*., Wu Y.* J. Med. Chem. 2022, 65(12):8444-8455.

4）Wu D, Zheng X, Liu R, Li Z, Jiang Z, Zhou Q, Huang Y, Wu XN, Zhang C, Huang YY*, Luo, H.-B*. Free energy perturbation (FEP)-guided scaffold hopping. Acta Pharm. Sin. B. 2022,12(3):1351-1362.

5）Xie G, Wu XN, Ling Y, Rui Y, Wu D, Zhou J, Li J, Lin S, Peng Q, Li Z, Wang H*, Luo, H.-B*. A novel inhibitor of N 6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. Acta Pharm. Sin. B. 2022 12(2):853-866.

6）Li, Z.; Li, H.; Yu, K.*; Luo, H.-B*. Perspective of drug design with high-performance computing. Natl. Sci. Rev. 2021, 8(12), nwab105.

7）Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X,* Luo H.-B.* Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J. Med. Chem. 2021, 64(18):13736-13751.

8）Wu Y, Wang Q, Jiang MY, Huang YY, Zhu Z, Han C, Tian YJ, Zhang B, Luo, H.-B*. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. J. Med. Chem. 2021, 64(13):9537-9549.  

9）Guo L, Wei RX, Sun R, Yang Q, Li GJ, Wang LY*, Luo H-B*, Feng M*. "Cytokine-microfactories" recruit DCs and deliver tumor antigens via gap junctions for immunotherapy. J. Control. Release. 2021, 337:417-430.

10）Li, Z.; Li X.; Huang, Y.Y.; Wu, Y.; Liu, R.; Zhou, L.; Lin, Y.; Wu, D.; Zhang, L.; Liu, H.; Xu, X.; Yu, K.; Zhang, Y.; Cui. J*.; Zhan, C.G*.; Wang, X*.; Luo, H.-B*. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc. Natl. Acad. Sci. U S A. 2020, 117(44): 27381-27387. 高被引論文。

11）Wu, Y.; Li, Z.; Zhao, Y.S.; Huang, Y.Y.; Jiang, M.Y.; Luo, H.-B*. Therapeutic targets and potential agents for the treatment of COVID-19. Med. Res. Rev. 2021, 41(3):1775-1797.

12）Sun J, Xiao Z, Haider A, Gebhard C, Xu H, Luo H-B, Zhang HT, Josephson L, Wang L, Liang SH. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery. J. Med. Chem. 2021, 64(11): 7083-7109.

13）Gao Y, Huang J, Zhou Q, Liu R, Zhang S, Zhang C, Huang YY, Li Z, Huang L, Wu D, Wu Y, Xiao L, Guo L*, Luo H-B.* Discovery of Highly Specific Catalytic-Site-Targeting Fluorescent Probes for Detecting Lysosomal PDE10A in Living Cells. ACS Chem. Biol. 2021, 16(5):857-863.

14）Yang Y, Zhang S, Zhou Q, Zhang C, Gao Y, Wang H, Li Z, Wu D, Wu Y, Huang YY*, Guo L*, Luo H-B.* Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharm. Sin. B. 2020,10(12):2339-2347.

15）Huang, Y.; Wu, X.N.; Zhou, Q.; Wu. Y.; Zheng. D, Li, Z.; Guo, L.; Luo, H.-B*. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors. J. Med. Chem. 2020, 63(24): 15852-15863.

16）Zhang T, Lai Z, Yuan S, Huang YY, Dong G, Sheng C*, Ke H*, Luo H.-B.* Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket. J. Med. Chem. 2020, 63(17):9828-9837.  

17）Wu Y, Tian YJ, Le ML, Zhang SR, Zhang C, Huang MX, Jiang MY, Zhang B, Luo H-B.* Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2020, 63(14): 7867-7879.

18）Jinhao Liang, Yi-You Huang, Qian Zhou, Yuqi Gao, Zhe Li, Deyan Wu, Si Yu, Lei Guo, Zhen Chen, Ling Huang, Steven H Liang, Xixin He*, Ruibo Wu*, Hai-Bin Luo.* Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia, J. Med. Chem. 2020, 63, 3370-3380

19）Xiaoyan Liu; Zhe Li; Shuai Liu; Jing Sun; Zhanghua Chen; Min Jiang; Qingling Zhang; Yinghua Wei; Xin Wang; Yi-You Huang; Yinyi Shi; Yanhui Xu; Huifang Xian; Fan Bai; Changxing Ou; Bei Xiong; Andrew M Lew; Jun Cui; Rongli Fang; Hui Huang; Jincun Zhao*; Xuechuan Hong*; Yuxia Zhang*; Fuling Zhou*; Hai-Bin Luo.* Potential therapeutic effects of dipyridamole to the severely ill , patients with COVID-19（12家機構參加本研究）Acta Pharm. Sin. B 2020, 10(7):1205-1215. 高被引論文。

20）Ma, Y.; Ye, Z.; Zhang, C.; Wang, X.; Li, H.W.; Wong, M.S.; Luo, H.-B.*; Xiao, L.* Deep Red Blinking Fluorophore for Nanoscopic Imaging and Inhibition of β-Amyloid Peptide Fibrillation. ACS Nano. 2020 ,14(9):11341-11351.

21）Li Z.; Zhao, Y.; Huifang Zhou, H.; Luo, H-B*.; Zhan, C.G.* Catalytic Roles of Coenzyme Pyridoxal-5′-phosphate (PLP) in PLP-Dependent Enzymes: Reaction Pathway for Methionine-γ-Lyase-Catalyzed l-Methionine Depletion. ACS Catalysis 2020, 10, 2198-2210.

22）Fan Zhang, Tianyue An, Xiaowen Tang, Jiachen Zi*, Hai-Bin Luo*, Ruibo Wu*. Enzyme Promiscuity versus Fidelity in Two Sesquiterpene Cyclases (TEAS versus ATAS). ACS Catalysis 2020, 10, 1470-1484.

23）Li, Z.; Huang, Y.; Wu, Y.; Chen, J.; Wu, D.; Zhan, C.G.*; Luo, H.-B*. Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor of Phosphodiesterase-10. J. Med. Chem. 2019, 62, 2099-2111.

24）Wu, Y.; Zhou, Q.; Zhang,T.; Li, Z.; Chen, Y.P.; Zhang, P.; Yu, Y.F.; Geng, H.; Tian, Y.J.; Zhang, C.; Wang, Y.; Chen, J.W.*; Chen, Y. *; Luo, H.-B.* Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. J. Med. Chem. 2019, 62, 4218-4224.

25）Huang, Y.Y.; Yu, Y.; Zhang, C.; Chen, Y.; Zhou, Q.; Li, Z.; Zhou, S.; Li, Z.; Guo, L.; Wu, D.*; Wu, Y.*; Luo, H-B*. Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. J. Med. Chem. 2019, 62, 3707-3721.

26）Senling Feng; Huifang Zhou; Deyan Wu; Dechong Zheng; Biao Qu; Ruiming; Liu; Chen Zhang; Zhe Li; Ying Xie;* Hai-Bin Luo.* Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents. Acta Pharm. Sin. B. 2020, 10, 327-343.

27）Wu, D.W.; Huang Y.; Chen, Y.; Huang, Y.; Geng, H.; Zhang, T.; Zhang, C.; Li, Z.; Guo, L.; Chen, J. W.; Luo, L.-B.* Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. J. Med. Chem., 2018, 61, 8468-8473.

28）Wu, D.W.; Zhang, T.H.; Chen, Y.; Huang, Y.; Geng, H.; Yu, Y.; Zhang, C., Lai, Z.W.; Wu, Y.; Guo, X.; Chen, J. W.*; Luo, L.-B.* Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. J. Med. Chem. 2017, 60(15): 6622-6637.

29）Wu, Y.; Li, Z.; Huang, Y.-Y.; Wu, D.Y.; Luo, L.-B.* Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease. J. Med. Chem. 2018, 61 (13), 5467–5483.

30）Wu, X.N.; Huang, Y.D.; Li, J.X.; Yu, Y.F.; Qian, Z.; Zhang, C.; Wu Y*.; Luo H.-B.* Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors. Acta Pharm. Sin. B 2018, 8(4), 615-628.

31）Huang, Y.; Liu, X.; Wu, D.; Tang, G.; Lai, Z.; Zheng, X. *; Yin. S. *; Luo, H.-B. * The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata. Biochem. Pharmacol. 2017, 130, 51-59.

32）Zhang, C.; Feng, L.J.; Huang, Y.; Wu, D.; Li, Z.; Zhou, Q.; Wu, Y. *; Luo, H.-B.* Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay. J. Chem. Inf. Model. 2017, 57, 355-364.

33）Li, Z.; Wu, Y., Feng, L.J.; Wu, R.*; Luo, H.-B.* Ab Initio QM/MM Study Shows a Highly Dissociated S_N2 Hydrolysis mechanism for the cGMP-specific phosphodiesterase-5. J. Chem. Theory Comput. 2015, 10, 5448-5457.

34）Shao, Y.X.; Huang, M.; Cui, W.; Feng, L.J.; Wu, Y.; Cai, Y.; Li, Z.; Zhu, X.; Liu, P.; Wan, Y.;* Ke, H.*; Luo, H.-B.* Discovery of a phosphodiesterase-9A inhibitor as a potential hypoglycemic agent. J. Med. Chem. 2014, 57, 10304-130313.

35）Shang, N.N.; Shao, Y.X.; Cai, Y.H.; Guan, M.; Huang, M.; Cui, W.; He, L.; Yu, Y.J.; Huang, L.; Li, Z.; Bu, X. Z.*; Ke, H.*; Luo, H.-B.* Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. Biochem. Pharmacol.2014, 89: 86-98.

36）Huang, Y.Y.; Li, Z.; Cai, Y.H.; Feng, L.J.; Wu, Y.; Li, X.; Luo, H.-B.* The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: A modeling study. J. Chem. Inf. Model. 2013, 53, 3044-3053. PMID: 24180640.

37）Li, Z.; Cai, Y.H.; Cheng, Y.K.; Lu, X.; Shao, Y.X.; Li, X.; Liu, M.; Liu, P.; Luo, H.-B.* Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay. J. Chem. Inf. Model. 2013, 53, 972-981.PMID: 23517293.

38）Meng, F.; Hou, J.; Shao, Y. X.; Wu, P. Y.; Huang, M.; Zhu, X.; Cai, Y. H.; Li, Z.; Xu, J.; Liu, P. Q.; Luo, H.-B.*; Wan, Y.*; Ke, H*. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J. Med. Chem. 2012, 55(19): 8549-8558. PMID: 22985069.

8.榮譽獎勵

• 中國藥學會施維雅青年藥物化學獎（2014）

• 中國化學會青年計算化學家獎（2019）

• 國際超算“戈登貝爾”提名獎(2021)